Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A

• Melanie M. Erzinger,

  Affiliation Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland

  ⨯
• Cédric Bovet,

  Affiliation Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland

  ⨯
• Katrin M. Hecht,

  Affiliation Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland

  ⨯
• Sabine Senger,

  Affiliation Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland

  ⨯
• Pascale Winiker,

  Affiliation Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland

  ⨯
• Nadine Sobotzki,

  Affiliation Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland

  ⨯
• Simona Cristea,

  Affiliations Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland, SIB Swiss Institute of Bioinformatics, Basel, Switzerland

  ⨯
• Niko Beerenwinkel,

  Affiliations Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland, SIB Swiss Institute of Bioinformatics, Basel, Switzerland

  ⨯
• Jerry W. Shay,

  Affiliation Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Giancarlo Marra,

  Affiliation Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland

  ⨯
• Bernd Wollscheid,

  Affiliations Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland, Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland, BioMedical Proteomics Platform (BMPP), ETH Zurich, Zurich, Switzerland

  ⨯
• Shana J. Sturla

  * E-mail: sturlas@ethz.ch

  Affiliation Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland

  ⨯